Action:
De-scheduling of drug to conform to DEA
Action 5667
General Information
| Action Summary |
As specified in § 54.1-3443 (E), the Board has acted to de-schedule a drug (epidiolex) in the Virginia Drug Control Act in accordance with actions of the U. S. Drug Enforcement Act (DEA) “after the expiration of 30 days from publication in the Federal Register of a final or interim final order or rule.” |
| Chapters Affected |
Only affects this chapter.
|
| Executive Branch Review |
This Action is exempt from Article 2 of the Administrative Process Act.
The normal executive branch review process is not required. As such, it can be submitted directly for publication and
is effective upon publication.
Exempt Citation:
54.1-3443 (E) and 2.2-4006
|
| RIS Project |
Yes [6584] |
| New Periodic Review |
This action will not be used to conduct a new periodic review.
|
Stages
Stages associated with this regulatory action.
| Stage ID |
Stage Type |
Status |
|
9168
|
Final
|
Stage complete. This regulation became effective on 02/17/2021. |
Contact Information
|
Name / Title:
|
Caroline Juran, RPh
/
Executive Director
|
|
Address:
|
9960 Mayland Drive
Suite 300
Richmond, VA 23233-1463
|
|
Email Address:
|
caroline.juran@dhp.virginia.gov
|
|
Phone:
|
(804)367-4456
FAX: (804)527-4472
TDD: ()-
|
This person is the primary contact for this chapter.
